Moderna, Inc. MRNA

Actualmente 2 alcistas, 1 bajistas — más polarizado.

Los analistas se mantienen estables en 2 alcistas frente a 1 bajistas.

3 analistas de YouTube cubren Moderna, Inc. (MRNA).

3 analistas han cubierto MRNA hasta ahora…

Opiniones de analistas

StockCharts TV7d ago

BULL$MRNACortoTécnico

ruptura por encima de $58 hasta $62 señala un cambio de tendencia

MRNA superó la resistencia previa cerca de $58, cerrando casi en $62, con un patrón de doble suelo y fuerte volumen que señala un posible cambio de tendencia.

Tras formar un doble suelo, MRNA mantuvo el soporte y rompió al alza hoy, cerrando cerca de $62 y superando los máximos previos alrededor de $58. Este movimiento técnico, especialmente si el dinero rota hacia áreas defensivas, respalda un caso alcista.

"This Market Rally Faces A Big Test"

Jack Corsellis43d ago

BULL$MRNACortoTécnico

Bullish on $MRNA: ORB works in flush/EMA contexts — avoided when the setup is near “extended/no-no” index conditions.

MRNA can fit the ORB framework when the indexes are flushing and the stock is near key daily moving averages, because the “no-no” zones are described as occurring when the index is extended the other way.

MRNA is framed as a tradable ORB candidate specifically when the index action lines up with mean-reversion and snapback behavior around daily moving averages. The risk note is contextual: the approach warns against taking the same type of setups when the index tape is in the unfavorable “no-no” state.

"The Trading Session That Nearly Ruined My Month (+17% Recovery)"

Valuetainment48d ago

BEAR$MRNA

next-gen shot framed as ongoing pathogen risk signal

MRNA appears to be preparing next-generation mRNA shots related to this “antivirus” threat (citing work from 2024 with Korea University), which he frames as evidence the vaccine program is implicitly tied to ongoing pathogen risk.

Next-generation mRNA vaccine development tied to 2024 research with Korea University is framed as implicit evidence that the vaccine program is linked to continuing pathogen risk rather than a standalone commercial opportunity.

""Mass Negligent Homicide" - Hantavirus Outbreak Surges As Fauci Deadline Nears"

Aún no han aparecido presentaciones oficiales para MRNA.